{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T20:59:13Z","timestamp":1788209953650,"version":"build-2803163510"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T00:00:00Z","timestamp":1490832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Owing to lagging or insufficient neo-angiogenesis, hypoxia is a feature of most solid tumors. Hypoxic tumor regions contribute to resistance against antiproliferative chemotherapeutics, radiotherapy and immunotherapy. Targeting cells in hypoxic tumor areas is therefore an important strategy for cancer treatment. Most approaches for targeting hypoxic cells focus on the inhibition of hypoxia adaption pathways but only a limited number of compounds with the potential to specifically target hypoxic tumor regions have been identified. By using tumor spheroids in hypoxic conditions as screening system, we identified a set of compounds, including the phenothiazine antipsychotic Fluphenazine, as hits with novel mode of action. Fluphenazine functionally inhibits acid sphingomyelinase and causes cellular sphingomyelin accumulation, which induces cancer cell death specifically in hypoxic tumor spheroids. Moreover, we found that functional inhibition of acid sphingomyelinase leads to overactivation of hypoxia stress-response pathways and that hypoxia-specific cell death is mediated by the stress-responsive transcription factor ATF4. Taken together, the here presented data suggest a novel, yet unexplored mechanism in which induction of sphingolipid stress leads to the overactivation of hypoxia stress-response pathways and thereby promotes their pro-apoptotic tumor-suppressor functions to specifically kill cells in hypoxic tumor areas.<\/jats:p>","DOI":"10.1038\/cddis.2017.130","type":"journal-article","created":{"date-parts":[[2017,3,30]],"date-time":"2017-03-30T12:49:21Z","timestamp":1490878161000},"page":"e2709-e2709","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Functional inhibition of acid sphingomyelinase by Fluphenazine triggers hypoxia-specific tumor cell death"],"prefix":"10.1038","volume":"8","author":[{"given":"Saskia","family":"Klutzny","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralf","family":"Lesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Keck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kaulfuss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Schlicker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolyn","family":"Sperl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland","family":"Neuhaus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Mowat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Steckel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Riefke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Prechtl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Parczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Steigemann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,3,30]]},"reference":[{"key":"BFcddis2017130_CR1","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1158\/0008-5472.CAN-11-3059","volume":"72","author":"AH Kyle","year":"2012","unstructured":"Kyle AH, Baker JH, Minchinton AI . Targeting quiescent tumor cells via oxygen and IGF-I supplementation. Cancer Res 2012; 72: 801\u2013809.","journal-title":"Cancer Res"},{"key":"BFcddis2017130_CR2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1146\/annurev-pathol-012513-104720","volume":"9","author":"GL Semenza","year":"2014","unstructured":"Semenza GL . Oxygen sensing, hypoxia-inducible factors, and disease pathophysiology. Annu Rev Pathol 2014; 9: 47\u201371.","journal-title":"Annu Rev Pathol"},{"key":"BFcddis2017130_CR3","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1038\/sj.bjc.6604929","volume":"100","author":"JA Nagy","year":"2009","unstructured":"Nagy JA, Chang SH, Dvorak AM, Dvorak HF . Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer 2009; 100: 865\u2013869.","journal-title":"Br J Cancer"},{"key":"BFcddis2017130_CR4","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1158\/1541-7786.MCR-06-0150","volume":"4","author":"C Koumenis","year":"2006","unstructured":"Koumenis C, Wouters BG . \"Translating\" tumor hypoxia: unfolded protein response (UPR)-dependent and UPR-independent pathways. Mol Cancer Res 2006; 4: 423\u2013436.","journal-title":"Mol Cancer Res"},{"key":"BFcddis2017130_CR5","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1007\/s10555-007-9055-1","volume":"26","author":"P Vaupel","year":"2007","unstructured":"Vaupel P, Mayer A . Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26: 225\u2013239.","journal-title":"Cancer Metastasis Rev"},{"key":"BFcddis2017130_CR6","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1016\/j.bcp.2013.02.017","volume":"85","author":"M Rebucci","year":"2013","unstructured":"Rebucci M, Michiels C . Molecular aspects of cancer cell resistance to chemotherapy. Biochem Pharmacol 2013; 85: 1219\u20131226.","journal-title":"Biochem Pharmacol"},{"key":"BFcddis2017130_CR7","doi-asserted-by":"publisher","first-page":"813","DOI":"10.3390\/cancers6020813","volume":"6","author":"G Multhoff","year":"2014","unstructured":"Multhoff G, Radons J, Vaupel P . Critical role of aberrant angiogenesis in the development of tumor hypoxia and associated radioresistance. Cancers 2014; 6: 813\u2013828.","journal-title":"Cancers"},{"key":"BFcddis2017130_CR8","doi-asserted-by":"publisher","first-page":"553","DOI":"10.4155\/fmc.13.17","volume":"5","author":"SK Burroughs","year":"2013","unstructured":"Burroughs SK, Kaluz S, Wang D, Wang K, Van Meir EG, Wang B . Hypoxia inducible factor pathway inhibitors as anticancer therapeutics. Future Med Chem 2013; 5: 553\u2013572.","journal-title":"Future Med Chem"},{"key":"BFcddis2017130_CR9","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/nrc3064","volume":"11","author":"WR Wilson","year":"2011","unstructured":"Wilson WR, Hay MP . Targeting hypoxia in cancer therapy. Nat Rev Cancer 2011; 11: 393\u2013410.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2017130_CR10","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1158\/1535-7163.MCT-08-0198","volume":"7","author":"R Sullivan","year":"2008","unstructured":"Sullivan R, Pare GC, Frederiksen LJ, Semenza GL, Graham CH . Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 2008; 7: 1961\u20131973.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2017130_CR11","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.drup.2011.03.001","volume":"14","author":"N Rohwer","year":"2011","unstructured":"Rohwer N, Cramer T . Hypoxia-mediated drug resistance: novel insights on the functional interaction of HIFs and cell death pathways. Drug Resist Updat 2011; 14: 191\u2013201.","journal-title":"Drug Resist Updat"},{"key":"BFcddis2017130_CR12","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1038\/nrc2501","volume":"8","author":"BG Wouters","year":"2008","unstructured":"Wouters BG, Koritzinsky M . Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 2008; 8: 851\u2013864.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2017130_CR13","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1038\/onc.2009.441","volume":"29","author":"GL Semenza","year":"2010","unstructured":"Semenza GL . Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 2010; 29: 625\u2013634.","journal-title":"Oncogene"},{"key":"BFcddis2017130_CR14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc704","volume":"2","author":"AL Harris","year":"2002","unstructured":"Harris AL . Hypoxia\u2014a key regulatory factor in tumour growth. Nat Rev Cancer 2002; 2: 38\u201347.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2017130_CR15","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nrc3800","volume":"14","author":"M Wang","year":"2014","unstructured":"Wang M, Kaufman RJ . The impact of the endoplasmic reticulum protein-folding environment on cancer development. Nat Rev Cancer 2014; 14: 581\u2013597.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2017130_CR16","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.tips.2012.01.005","volume":"33","author":"GL Semenza","year":"2012","unstructured":"Semenza GL . Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy. Trends Pharmacol Sci 2012; 33: 207\u2013214.","journal-title":"Trends Pharmacol Sci"},{"key":"BFcddis2017130_CR17","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.ccr.2013.08.003","volume":"24","author":"NH Petersen","year":"2013","unstructured":"Petersen NH, Olsen OD, Groth-Pedersen L, Ellegaard AM, Bilgin M, Redmer S et al. Transformation-associated changes in sphingolipid metabolism sensitize cells to lysosomal cell death induced by inhibitors of acid sphingomyelinase. Cancer Cell 2013; 24: 379\u2013393.","journal-title":"Cancer Cell"},{"key":"BFcddis2017130_CR18","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1158\/1535-7163.MCT-13-0084","volume":"12","author":"AM Ellegaard","year":"2013","unstructured":"Ellegaard AM, Groth-Pedersen L, Oorschot V, Klumperman J, Kirkegaard T, Nylandsted J et al. Sunitinib and SU11652 inhibit acid sphingomyelinase, destabilize lysosomes, and inhibit multidrug resistance. Mol Cancer Ther 2013; 12: 2018\u20132030.","journal-title":"Mol Cancer Ther"},{"key":"BFcddis2017130_CR19","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1242\/jeb.024067","volume":"212","author":"M Huss","year":"2009","unstructured":"Huss M, Wieczorek H . Inhibitors of V-ATPases: old and new players. J Exp Biol 2009; 212: 341\u2013346.","journal-title":"J Exp Biol"},{"key":"BFcddis2017130_CR20","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.chembiol.2010.12.015","volume":"18","author":"OA Ulanovskaya","year":"2011","unstructured":"Ulanovskaya OA, Cui J, Kron SJ, Kozmin SA . A pairwise chemical genetic screen identifies new inhibitors of glucose transport. Chem Biol 2011; 18: 222\u2013230.","journal-title":"Chem Biol"},{"key":"BFcddis2017130_CR21","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1016\/0005-2736(78)90034-2","volume":"510","author":"R Deves","year":"1978","unstructured":"Deves R, Krupka RM . Cytochalasin B and the kinetics of inhibition of biological transport. A case of asymmetric binding to the glucose carrier. Biochim Biophys Acta 1978; 510: 339\u2013348.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis2017130_CR22","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.metabol.2015.10.007","volume":"65","author":"CC Barron","year":"2016","unstructured":"Barron CC, Bilan PJ, Tsakiridis T, Tsiani E . Facilitative glucose transporters: implications for cancer detection, prognosis and treatment. Metabolism 2016; 65: 124\u2013139.","journal-title":"Metabolism"},{"key":"BFcddis2017130_CR23","doi-asserted-by":"publisher","first-page":"4633","DOI":"10.1038\/sj.onc.1209597","volume":"25","author":"H Pelicano","year":"2006","unstructured":"Pelicano H, Martin DS, Xu RH, Huang P . Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633\u20134646.","journal-title":"Oncogene"},{"key":"BFcddis2017130_CR24","doi-asserted-by":"publisher","first-page":"4915","DOI":"10.1016\/j.bmcl.2014.09.041","volume":"24","author":"C Granchi","year":"2014","unstructured":"Granchi C, Fancelli D, Minutolo F . An update on therapeutic opportunities offered by cancer glycolytic metabolism. Bioorg Med Chem Lett 2014; 24: 4915\u20134925.","journal-title":"Bioorg Med Chem Lett"},{"key":"BFcddis2017130_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0893-133X(96)00187-X","volume":"16","author":"P Seeman","year":"1997","unstructured":"Seeman P, Corbett R, Van Tol HHM . Atypixal neuroleptics have low affinity for dopamine D2 receptor or are selective for D4 receptors. Neuropsychpoharmacology 1997; 16: 93\u2013110.","journal-title":"Neuropsychpoharmacology"},{"key":"BFcddis2017130_CR26","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/0014-2999(96)00451-7","volume":"313","author":"B Karolewicz","year":"1996","unstructured":"Karolewicz B, Antkiewicz-Michaluk L, Michaluk J, Vetulani J . Different effects of chronic administration of haloperidol and pimozide on dopamine metabolism in the rat brain. Eur J Pharmacol 1996; 313: 181\u2013186.","journal-title":"Eur J Pharmacol"},{"key":"BFcddis2017130_CR27","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1006\/exnr.1994.1207","volume":"130","author":"CA Fox","year":"1994","unstructured":"Fox CA, Mansour A, Watson SJJ . The effects of haloperidol on dopamine receptor gene expression. Exp Neurol 1994; 130: 288\u2013303.","journal-title":"Exp Neurol"},{"key":"BFcddis2017130_CR28","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","volume":"280","author":"H Schoemaker","year":"1997","unstructured":"Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther 1997; 280: 83\u201397.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFcddis2017130_CR29","doi-asserted-by":"publisher","first-page":"7513","DOI":"10.1073\/pnas.83.19.7513","volume":"83","author":"JP Galizzi","year":"1986","unstructured":"Galizzi JP, Fosset M, Romey G, Laduron P, Lazdunski M . Neuroleptics of the diphenylbutylpiperidine series are potent calcium channel inhibitors. Proc Natl Acad Sci USA 1986; 83: 7513\u20137517.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2017130_CR30","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1177\/019262339702500111","volume":"25","author":"WH Halliwell","year":"1997","unstructured":"Halliwell WH . Cationic amphiphilic drug-induced phospholipidosis. Toxicol Pathol 1997; 25: 53\u201360.","journal-title":"Toxicol Pathol"},{"key":"BFcddis2017130_CR31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.ebiom.2016.06.013","volume":"9","author":"AM Ellegaard","year":"2016","unstructured":"Ellegaard AM, Dehlendorff C, Vind AC, Anand A, Cederkvist L, Petersen NH et al. Repurposing cationic amphiphilic antihistamines for cancer treatment. EBioMedicine 2016; 9: 130\u2013139.","journal-title":"EBioMedicine"},{"key":"BFcddis2017130_CR32","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3389\/fphys.2014.00331","volume":"5","author":"N Beckmann","year":"2014","unstructured":"Beckmann N, Sharma D, Gulbins E, Becker KA, Edelmann B . Inhibition of acid sphingomyelinase by tricyclic antidepressants and analogons. Front Physiol 2014; 5: 331.","journal-title":"Front Physiol"},{"key":"BFcddis2017130_CR33","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1002\/cmdc.201200306","volume":"7","author":"M Muehlbacher","year":"2012","unstructured":"Muehlbacher M, Tripal P, Roas F, Kornhuber J . Identification of drugs inducing phospholipidosis by novel in vitro data. ChemMedChem 2012; 7: 1925\u20131934.","journal-title":"ChemMedChem"},{"key":"BFcddis2017130_CR34","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1093\/toxsci\/kfj067","volume":"90","author":"T Kasahara","year":"2006","unstructured":"Kasahara T, Tomita K, Murano H, Harada T, Tsubakimoto K, Ogihara T et al. Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential. Toxicol Sci 2006; 90: 133\u2013141.","journal-title":"Toxicol Sci"},{"key":"BFcddis2017130_CR35","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.tiv.2010.12.010","volume":"25","author":"S Nadanaciva","year":"2011","unstructured":"Nadanaciva S, Lu S, Gebhard DF, Jessen BA, Pennie WD, Will Y . A high content screening assay for identifying lysosomotropic compounds. Toxicol In Vitro 2011; 25: 715\u2013723.","journal-title":"Toxicol In Vitro"},{"key":"BFcddis2017130_CR36","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1073\/pnas.96.8.4432","volume":"96","author":"N Altan","year":"1999","unstructured":"Altan N, Chen Y, Schindler M, Simon SM . Tamoxifen inhibits acidification in cells independent of the estrogen receptor. Proc Natl Acad Sci USA 1999; 96: 4432\u20134437.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFcddis2017130_CR37","doi-asserted-by":"publisher","first-page":"e1193","DOI":"10.1038\/cddis.2014.156","volume":"5","author":"A Kondratskyi","year":"2014","unstructured":"Kondratskyi A, Yassine M, Slomianny C, Kondratska K, Gordienko D, Dewailly E et al. Identification of ML-9 as a lysosomotropic agent targeting autophagy and cell death. Cell Death Dis 2014; 5: e1193.","journal-title":"Cell Death Dis"},{"key":"BFcddis2017130_CR38","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1016\/j.bbalip.2012.08.013","volume":"1831","author":"JA Shayman","year":"2013","unstructured":"Shayman JA, Abe A . Drug induced phospholipidosis: an acquired lysosomal storage disorder. Biochim Biophys Acta 2013; 1831: 602\u2013611.","journal-title":"Biochim Biophys Acta"},{"key":"BFcddis2017130_CR39","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1242\/jcs.091181","volume":"126","author":"S Aits","year":"2013","unstructured":"Aits S, Jaattela M . Lysosomal cell death at a glance. J Cell Sci 2013; 126: 1905\u20131912.","journal-title":"J Cell Sci"},{"key":"BFcddis2017130_CR40","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1080\/15548627.2015.1063871","volume":"11","author":"S Aits","year":"2015","unstructured":"Aits S, Kricker J, Liu B, Ellegaard AM, Hamalisto S, Tvingsholm S et al. Sensitive detection of lysosomal membrane permeabilization by lysosomal galectin puncta assay. Autophagy 2015; 11: 1408\u20131424.","journal-title":"Autophagy"},{"key":"BFcddis2017130_CR41","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/cam4.112","volume":"2","author":"P Ellinghaus","year":"2013","unstructured":"Ellinghaus P, Heisler I, Unterschemmann K, Haerter M, Beck H, Greschat S et al. BAY 87-2243, a highly potent and selective inhibitor of hypoxia-induced gene activation has antitumor activities by inhibition of mitochondrial complex I. Cancer Med 2013; 2: 611\u2013624.","journal-title":"Cancer Med"},{"key":"BFcddis2017130_CR42","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1126\/science.1059796","volume":"292","author":"P Jaakkola","year":"2001","unstructured":"Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ et al. Targeting of HIF-\u03b1 to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science 2001; 292: 468\u2013472.","journal-title":"Science"},{"key":"BFcddis2017130_CR43","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.tibs.2012.06.004","volume":"37","author":"MY Koh","year":"2012","unstructured":"Koh MY, Powis G . Passing the baton: the HIF switch. Trends Biochem Sci 2012; 37: 364\u2013372.","journal-title":"Trends Biochem Sci"},{"key":"BFcddis2017130_CR44","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1074\/jbc.M113.507194","volume":"289","author":"ER Pereira","year":"2014","unstructured":"Pereira ER, Frudd K, Awad W, Hendershot LM . Endoplasmic reticulum (ER) stress and hypoxia response pathways interact to potentiate hypoxia-inducible factor 1 (HIF-1) transcriptional activity on targets like vascular endothelial growth factor (VEGF). J Biol Chem 2014; 289: 3352\u20133364.","journal-title":"J Biol Chem"},{"key":"BFcddis2017130_CR45","doi-asserted-by":"publisher","first-page":"3066","DOI":"10.1101\/gad.1250704","volume":"18","author":"SJ Marciniak","year":"2004","unstructured":"Marciniak SJ, Yun CY, Oyadomari S, Novoa I, Zhang Y, Jungreis R et al. CHOP induces death by promoting protein synthesis and oxidation in the stressed endoplasmic reticulum. Genes Dev 2004; 18: 3066\u20133077.","journal-title":"Genes Dev"},{"key":"BFcddis2017130_CR46","doi-asserted-by":"publisher","first-page":"3755","DOI":"10.1074\/jbc.M606461200","volume":"282","author":"HY Jiang","year":"2007","unstructured":"Jiang HY, Jiang L, Wek RC . The eukaryotic initiation factor-2 kinase pathway facilitates differential GADD45a expression in response to environmental stress. J Biol Chem 2007; 282: 3755\u20133765.","journal-title":"J Biol Chem"},{"key":"BFcddis2017130_CR47","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1038\/nrd2755","volume":"7","author":"I Kim","year":"2008","unstructured":"Kim I, Xu W, Reed JC . Cell death and endoplasmic reticulum stress: disease relevance and therapeutic opportunities. Nat Rev Drug Discov 2008; 7: 1013\u20131030.","journal-title":"Nat Rev Drug Discov"},{"key":"BFcddis2017130_CR48","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/ncb2738","volume":"15","author":"J Han","year":"2013","unstructured":"Han J, Back SH, Hur J, Lin YH, Gildersleeve R, Shan J et al. ER-stress-induced transcriptional regulation increases protein synthesis leading to cell death. Nat Cell Biol 2013; 15: 481\u2013490.","journal-title":"Nat Cell Biol"},{"key":"BFcddis2017130_CR49","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/jcp.2003.015032","volume":"57","author":"AE Greijer","year":"2004","unstructured":"Greijer AE, van der Wall E . The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004; 57: 1009\u20131014.","journal-title":"J Clin Pathol"},{"key":"BFcddis2017130_CR50","doi-asserted-by":"publisher","first-page":"27540","DOI":"10.1038\/srep27540","volume":"6","author":"C-H Wu","year":"2016","unstructured":"Wu C-H, Bai L-Y, Tsai M-H, Chu P-C, Chiu C-F, Chen MY et al. Pharmacological exploitation of the phenothiazine antipsychotics to develop novel antitumor agents\u2013a drug repurposing strategy. Sci Rep 2016; 6: 27540.","journal-title":"Sci Rep"},{"key":"BFcddis2017130_CR51","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.ceb.2014.12.002","volume":"33","author":"R Volmer","year":"2015","unstructured":"Volmer R, Ron D . Lipid-dependent regulation of the unfolded protein response. Curr Opin Cell Biol 2015; 33: 67\u201373.","journal-title":"Curr Opin Cell Biol"},{"key":"BFcddis2017130_CR52","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/nature13119","volume":"508","author":"X Chen","year":"2014","unstructured":"Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M et al. XBP1 promotes triple-negative breast cancer by controlling the HIF1alpha pathway. Nature 2014; 508: 103\u2013107.","journal-title":"Nature"},{"key":"BFcddis2017130_CR53","doi-asserted-by":"publisher","first-page":"3610","DOI":"10.1182\/blood-2007-06-094441","volume":"110","author":"J K\u00f6ditz","year":"2007","unstructured":"K\u00f6ditz J, Nesper J, Wottawa M, Stiehl D, Camenisch G, Franke C et al. Oxygen-dependent ATF-4 stability is mediated by the PHD3 oxygen sensor. Blood 2007; 110: 3610\u20133617.","journal-title":"Blood"},{"key":"BFcddis2017130_CR54","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.canlet.2005.05.028","volume":"237","author":"J Zhou","year":"2006","unstructured":"Zhou J, Schmid T, Schnitzer S, Brune B . Tumor hypoxia and cancer progression. Cancer Lett 2006; 237: 10\u201321.","journal-title":"Cancer Lett"},{"key":"BFcddis2017130_CR55","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.15252\/embr.201642195","volume":"17","author":"K Pakos-Zebrucka","year":"2016","unstructured":"Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM . The integrated stress response. EMBO Rep 2016; 17: 1374\u20131395.","journal-title":"EMBO Rep"},{"key":"BFcddis2017130_CR56","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1038\/nrc1187","volume":"3","author":"GL Semenza","year":"2003","unstructured":"Semenza GL . Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003; 3: 721\u2013732.","journal-title":"Nat Rev Cancer"},{"key":"BFcddis2017130_CR57","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.yexcr.2014.01.017","volume":"323","author":"C Wenzel","year":"2014","unstructured":"Wenzel C, Riefke B, Grundemann S, Krebs A, Christian S, Prinz F et al. 3D high-content screening for the identification of compounds that target cells in dormant tumor spheroid regions. Exp Cell Res 2014; 323: 131\u2013143.","journal-title":"Exp Cell Res"},{"key":"BFcddis2017130_CR58","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","volume":"15","author":"MI Love","year":"2014","unstructured":"Love MI, Huber W, Anders S . Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 2014; 15: 550.","journal-title":"Genome Biol"},{"key":"BFcddis2017130_CR59","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 2005; 102: 15545\u201315550.","journal-title":"Proc Natl Acad Sci USA"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/cddis2017130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2017130","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/cddis.2017.130","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/www.nature.com\/articles\/cddis2017130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T19:36:31Z","timestamp":1750188991000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/cddis2017130"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,30]]},"references-count":59,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2017,3]]}},"alternative-id":["BFcddis2017130"],"URL":"https:\/\/doi.org\/10.1038\/cddis.2017.130","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,30]]},"assertion":[{"value":"19 December 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors are employees of Bayer AG.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}